Basic scientists and drug developers are accelerating innovations toward the goal of precision medicine. Regulators create pathways for timely patient access to precision medicines, including individualized therapies. Healthcare payors acknowledge … Read More
The NEWDIGS Initiative at MIT welcomes Flatiron Health as a new collaborator for the LEAPS Project
CAMBRIDGE, MA October 29, 2021 – Flatiron Health®, a world leader in transforming patients’ real-life experiences into knowledge to help accelerate improvements in cancer care and treatments, has joined the Massachusetts Institute … Read More
FoCUS Monthly Recap: September 2021
NEW RESOURCES Self-Insured Employers Workshop shares practical advice for covering cell and gene therapies In June FoCUS hosted a workshop for self-insured employers to help them understand the challenges and … Read More
Self-Insured Employers Workshop shares practical advice for covering cell and gene therapies
In June FoCUS hosted a workshop for self-insured employers to help them understand the challenges and potential solutions presented by new cell and gene therapies. In our event archive you … Read More
Upcoming book highlighting NEWDIGS Design Labs now available for pre-order
The LEAPS Project of the MIT NEWDIGS initiative is actively soliciting Use Cases for our workstream focused on methods innovation associated with “Integrating Evidence Using Meta-Analytic Approaches.” This methodology is … Read More
Rebranding: Adaptive Reimbursement is now Precision Reimbursement
Adaptive Reimbursement evolved as a collaboration of our NEWDIGS LEAPS and FoCUS Projects. The goal of LEAPS is to advance the knowledge and practice of Precision Medicine by modernizing how … Read More
Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020)
Ivica NA, Young CM. Healthcare. 2021; 9(8):1062. Chimeric antigen receptor and T-cell receptor (CAR-T/TCR-T) cellular immunotherapies have shown remarkable success in the treatment of some refractory B-cell malignancies, with potential … Read More
FoCUS Monthly Recap: June 2021
NEW WHITE PAPER Emerging market solutions for financing and reimbursement of durable cell and gene therapies The white paper reports the findings and analysis from a survey of organizations offering … Read More
Emerging market solutions for financing and reimbursement of durable cell and gene therapies
The FoCUS project was launched in 2016 with the aim of developing precision financing solutions that address the challenges and financial impact created by durable cell and gene therapies entering … Read More
FoCUS Monthly Recap: May 2021
NEW MEMBER CSL Behring joins FoCUS “CSL Behring strengthens our consortium’s perspectives on how to achieve patient impact with cutting-edge therapies,” said Gigi Hirsch, MD, executive director of NEWDIGS. “The … Read More